Reviewing Veru (NASDAQ:VERU) and Hero Technologies (OTCMKTS:HENC)

Veru (NASDAQ:VERU) and Hero Technologies (OTCMKTS:HENC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 0.2% of Hero Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Veru has a beta of -1.35, suggesting that its share price is 235% less volatile than the S&P 500. Comparatively, Hero Technologies has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Veru and Hero Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Hero Technologies	0	0	0	0	0.00

Veru currently has a consensus price target of $22.50, suggesting a potential upside of 822.13%. Given Veru’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Veru is more favorable than Hero Technologies.

Earnings and Valuation

This table compares Veru and Hero Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89 million	2.32	-$22.73 million	($1.26)	-1.94
Hero Technologies	N/A	N/A	N/A	N/A	N/A

Hero Technologies has lower revenue, but higher earnings than Veru.

Profitability

This table compares Veru and Hero Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-83.63%	-55.90%
Hero Technologies	N/A	N/A	N/A

Summary

Veru beats Hero Technologies on 6 of the 9 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Hero Technologies

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.